Literature Review : Study of molecular mechanism level of NSAID class of drugs as COX-2 inhibitors

Wildani Zakiyah; Sepvia Putri Sukma Wibowo; Nina Elyyana; Shiyami Aulia Nur Darmawan; Sepiyani Ayu Lestari; Nur Sa'diyyah; Jekmal Malau; Munir Alinu Mulki

Authors

Wildani Zakiyah Program Studi Farmasi Universitas Singaperbangsa Karawang, Indonesia
Sepvia Putri Sukma Wibowo Program Studi Farmasi Universitas Singaperbangsa Karawang, Indonesia
Nina Elyyana Program Studi Farmasi Universitas Singaperbangsa Karawang, Indonesia
Shiyami Aulia Nur Darmawan Program Studi Farmasi Universitas Singaperbangsa Karawang, Indonesia
Sepiyani Ayu Lestari Program Studi Farmasi Universitas Singaperbangsa Karawang, Indonesia
Nur Sa'diyyah Program Studi Farmasi Universitas Singaperbangsa Karawang, Indonesia
Jekmal Malau Program Studi Farmasi Universitas Singaperbangsa Karawang, Indonesia
Munir Alinu Mulki Program Studi Farmasi Universitas Singaperbangsa Karawang, Indonesia

Abstract

NSAIDs (Non-Steroid Anti-Inflammatory Drugs) are drugs that can treat pain and inflammation. The therapeutic effect of NSAIDs as anti-inflammatory analgesics is that they have the ability to inhibit the biosynthesis of prostaglandins which are pain mediators. This prostaglandin has a major role in inhibiting the COX enzyme (cyclooxygenase) in which COX has two isoforms, namely COX1 isoenzyme (non-selective) and COX2 isoenzyme (selective). Tricyclic COX-2 selective inhibitors work by blocking COX-2. COX-2 binds to PD-L1 via the PGE2 pathway and affects macrophages in suppressing myeloid. COX-2 has functions including producing reactive oxygen species that are responsible for DNA damage, activating substances that deviate from intracellular pathways such as the MAPK and PI3 K/AKT pathways, activating STAT3, inducing Bcl-2, and producing growth factors including growth factors. epidermal (EGF)) and fibroblast growth factor (FGF).

References

E. Kusumastuti, J. Handajani, and Heni Susilowati, “Ekspresi COX-2 dan Jumlah Neutrofil Fase Inflamasi pada Proses Penyembuhan Luka Setelah Pemberian Sistemik Ekstrak Etanolik Rosela (Hibiscus sabdariffa) (studi in vivo pada Tikus Wistar),” Majalah Kedokteran Gigi Indonesia, vol. 21, no. 1, pp. 13–19, 2014.

Y. Aulia, F. Safitri, and R. Fadilah, “EFEK ANTI INFLAMASI EKSTRAK ETANOL WORTEL (DAUCUS CAROTA L.) TERHADAP TIKUS STRAIN WISTAR (RATTUS NOVERGICUS) YANG DIINJEKSI KARAGENAN,” Saintika Medika: Jurnal Ilmu Kesehaan dan Kedokteran Keluarga, vol. 9, no. 2, pp. 65–69, 2013.

M. Soleha, A. Isnawati, N. Fitri, R. Adelina, H. T. Soblia, and W. Winarsih, “Profil Penggunaan Obat Antiinflamasi Nonstreoid di Indonesia,” Jurnal Kefarmasian Indonesia, pp. 109–117, Oct. 2018, doi: 10.22435/jki.v8i2.316.

T. Eko, “PENGGUNAAN COXIB DALAM TATA LAKSANA NYERI NOSISEPTIF,” Medicina Jurnal Ilmiah Kedokteran, vol. 43, no. 1, pp. 23–30, 2012.

D. Kresnadi and K. Mulyo, “PERBANDINGAN PENGARUH PEMBERIAN ANALGETIK COX-2 DENGAN ASAM MEFENAMAT TERHADAP RASA NYERI PASCA ODONTEKTOMI (IMPAKSI KELAS 1, MOLAR 3 RAHANG BAWAH),” 2016.

Y. Bare, “Interaction Phloroglucinol as inflammation therapy through Cyclooxygenase-2 (COX-2) gene inhibition,” Jurnal Ilmiah Medicamento, vol. 8, no. 1, pp. 14–21, Mar. 2022, doi: 10.36733/medicamento.v8i1.3162.

S. J. Desai, B. Prickril, and A. Rasooly, “Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer,” Nutrition and Cancer, vol. 70, no. 3. Routledge, pp. 350–375, Apr. 03, 2018. doi: 10.1080/01635581.2018.1446091.

O. R. Sadeq, “The effects of mini-dose aspirin on hepatic functions. View project,” 2018. [Online]. Available: https://www.researchgate.net/publication/324418484

R. P. Hidayat, “N-ACETYLCYSTEINE SEBAGAI TERAPI TOKSISITAS ACETAMINOPHEN,” Jurnal Medika Hutama, vol. 2, no. 1, pp. 231–237, 2020, [Online]. Available: http://jurnalmedikahutama.com

I. N. Widjaja, K. Cahyadi, A. Wahyudhie, and I. MAG Wirasuta, “Pengembangan Metode Identifikasi Indometasin dengan KLT-Spektrofotodensitometri,” Jurnal Farmasi Udayana, vol. 2, no. 1, pp. 17–24, 2013.

W. Chen and D. Ouyang, “Investigation of molecular dissolution mechanism of ketoprofen binary and ternary solid dispersions by molecular dynamics simulations,” Mol Simul, vol. 43, no. 13–16, pp. 1074–1080, 2017, doi: 10.1080/08927022.2017.1321755.

D. I. Dinata, H. Suryatno, I. Musfiroh, and S. E. Suherman, “Simulasi Docking Molekuler Senyawa Xanthorrhizol sebagai Antiinflamasi terhadap Enzim COX-1 dan COX-2,” Indonesian Journal of Pharmaceutical Science and Technology, vol. 1, no. 1, pp. 7–13, 2014, [Online]. Available: www.pdb.com.

B. J. Orlando, M. J. Lucido, and M. G. Malkowski, “The structure of ibuprofen bound to cyclooxygenase-2,” J Struct Biol, vol. 189, no. 1, pp. 62–66, Jan. 2015, doi: 10.1016/j.jsb.2014.11.005.

R. Kumar Vishwakarma and D. S. Negi, “THE DEVELOPMENT OF COX-1 AND COX-2 INHIBITORS: A REVIEW,” Int J Pharm Sci Res, vol. 11, no. 8, p. 3544, 2020, doi: 10.13040/IJPSR.0975-8232.11(8).3544-55.

R. Ruslin et al., “The Search for Cyclooxygenase-2 (COX-2) Inhibitors for the Treatment of Inflammation Disease: An in-silico Study,” J Multidiscip Healthc, vol. 15, pp. 783–791, 2022, doi: 10.2147/JMDH.S359429.

S. S. Ayoub, “Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action,” Temperature, vol. 8, no. 4, pp. 1–22, 2021, doi: 10.1080/23328940.2021.1886392.

E. E. P. S. Adiansyah, H. Ariyani, and Hendera, “STUDI LITERATUR EFEK PENGGUNAAN NON-STEROIDAL ANTI INFLAMMATORY DRUGS (NSAID) PADA SISTEM GASTROINTESTINAL (Literature Study Of The Non-Steroidal Anti Inflammatory Drugs (NSAIDs) On The Gastrointestinal System),” Journal of Current Pharmaceutical Sciences, vol. 5, no. 1, pp. 418–428, 2021.

G. Botti et al., “COX-2 expression positively correlates with PD-L1 expression in human melanoma cells,” J Transl Med, vol. 15, no. 1, pp. 1–12, Feb. 2017, doi: 10.1186/s12967-017- 1150-7.

R. Kumar Vishwakarma and D. S. Negi, “THE DEVELOPMENT OF COX-1 AND COX-2 INHIBITORS: A REVIEW,” Int J Pharm Sci Res, vol. 11, no. 8, p. 3544, 2020, doi: 10.13040/IJPSR.0975-8232.11(8).3544-55.

J. J. P, S. L. Manju, K. R. Ethiraj, and G. Elias, “Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach,” European Journal of Pharmaceutical Sciences, vol. 121. Elsevier B.V., pp. 356–381, Aug. 30, 2018. doi: 10.1016/j.ejps.2018.06.003.

C. Y. Zhang et al., “COX-2/sEH Dual Inhibitor PTUPB Attenuates Epithelial-Mesenchymal Transformation of Alveolar Epithelial Cells via Nrf2-Mediated Inhibition of TGF- β 1/Smad Signaling,” Oxid Med Cell Longev, vol. 2022, 2022, doi: 10.1155/2022/5759626.

T. Jayakumar et al., “Anti-Inflammatory Mechanism of An Alkaloid Rutaecarpine in LTA-Stimulated RAW 264.7 Cells: Pivotal Role on NF-κB and ERK/p38 Signaling Molecules,” Int J Mol Sci, vol. 23, no. 11, Jun. 2022, doi: 10.3390/ijms23115889.